Articles Published in 2013

Moderna Therapeutics names Joseph Bolen president of R&D

Thursday, August 1, 2013 12:27 PM

Moderna Therapeutics, developing messenger RNA therapeutics, a new treatment modality to enable the in vivo production of therapeutic proteins, has hired Joseph Bolen, Ph.D., as its president of R&D.

More... »

DIA names Barbara Lopez Kunz global chief executive

Thursday, August 1, 2013 12:00 PM

DIA, a neutral, global, professional member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related healthcare products, has named Barbara Lopez Kunz global chief executive, to lead the organization beginning in September. Kunz brings worldwide leadership experience to DIA as former president of the global health and life sciences business at Battelle, an international science and technology nonprofit organization that explores emerging areas of science, develops and commercializes technology and manages laboratories.

More... »

Bionomics, Merck ink $172 million research collaboration

Thursday, August 1, 2013 11:31 AM

Bionomics has announced an agreement with Merck to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain. The initial period of the research program will be two years. 

More... »

La Jolla Institute, Kyowa Hakko Kirin extend research collaboration

Thursday, August 1, 2013 11:00 AM

La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California (KKC), a global specialty pharmaceutical company, have signed a new partnership agreement through the end of 2018.

More... »

SAGE Therapeutics awarded NIH grant for Fragile X Syndrome

Thursday, August 1, 2013 10:30 AM

The NIH has granted SAGE Therapeutics, a neuroscience product-focused company creating novel medicines to treat central nervous system (CNS) disorders, an award potentially worth up to $10 million to support the company's development of a novel drug which could be used to treat anxiety and social deficits in patients with Fragile X Syndrome (FXS).

More... »

Actelion to acquire Ceptaris

Thursday, August 1, 2013 10:00 AM

San Francisco, Calif.-based pharmaceutical company Actelion will acquire Ceptaris Therapeutics, contingent upon certain closing conditions, including FDA approval of Ceptaris' product, VALCHLOR.

More... »

Certara launches Cardiac Safety Simulator

Thursday, August 1, 2013 09:30 AM

St. Louis-based Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, has launched its Cardiac Safety Simulator (CSS), based on an in-silico model of human ventricular heart cells.

More... »

RPS, PRA to merge under KKR ownership

Wednesday, July 31, 2013 01:51 PM

Global investment firm KKR has signed a definitive agreement to acquire ReSearch Pharmaceutical Services (RPS), a global CRO, from Warburg Pincus.

More... »

Quanterix launches Simoa Single Molecule Array technology

Wednesday, July 31, 2013 11:53 AM

Quanterix, a company focused on high definition diagnostics, has launched its Single Molecule Array (Simoa) technology, making it commercially available for the first time on a fully automated platform for research use only. Simoa enables life science researchers to explore biomarkers and pathways with greater sensitivity and precision, allowing the development of new diagnostic tests and improved treatment of diseases in oncology, neurology and cardiology.

More... »

AstraZeneca, FibroGen collaborate to develop and commercialize FG-4592

Wednesday, July 31, 2013 11:51 AM

AstraZeneca and biotechnology company FibroGen have entered into a collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), which also may be extended to other anemia indications.

More... »